Institutional Ownership
Perspective Therapeutics Inc
CUSIP 46489V104COMCATXQ1 2026
13D / 13G Filings
12
Schedule 13D/13G on record
Beneficial Filers
5
Distinct reporting persons
Largest Stake
19.9%
Max % of class reported
Institutional Holders
2
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
12 filings · latest Feb 5, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 5, 2026 | Farallon Capital Partners, L.P. | 13G/A | 8.2% | 5.43M | SEC |
| 2 | Nov 12, 2025 | Farallon Capital Partners, L.P. | 13G/A | 5.1% | 3.48M | SEC |
| 3 | May 8, 2025 | Farallon Capital Partners, L.P. | 13G/A | 8.8% | 6.02M | SEC |
| 4 | Feb 5, 2025 | Farallon Capital Partners, L.P. | 13G/A | 7.6% | 5.32M | SEC |
| 5 | Nov 14, 2024 | Farallon Capital Partners, L.P. | 13G | 0.5% | 367.4K | SEC |
| 6 | Apr 19, 2024 | Commodore Capital LP | 13G | 6.6% | 38.91M | SEC |
| 7 | Mar 8, 2024 | Lantheus Holdings, Inc. | 13D/A | 19.9% | 116.77M | SEC |
| 8 | Feb 5, 2024 | Schultz Michael K | 13G/A | 5.9% | 16.78M | SEC |
| 9 | Feb 5, 2024 | Johnson Frances | 13G/A | 5.9% | 16.78M | SEC |
| 10 | Feb 1, 2024 | Lantheus Holdings, Inc. | 13D | 10.7% | 56.34M | SEC |
2 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Perspective Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Portland Investment Counsel Inc. | 250.0K | $1.04M |
| 2 | Vestor Capital, LLC | 1.10M | $4.6K |